Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.

Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS.

Pediatr Blood Cancer. 2013 May;60(5):828-35. doi: 10.1002/pbc.24459. Epub 2013 Jan 17.

PMID:
23335275
2.

Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.

Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

J Clin Pharm Ther. 2012 Apr;37(2):173-81. doi: 10.1111/j.1365-2710.2011.01276.x. Epub 2011 May 18.

PMID:
21592159
3.

Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.

Armstrong EP, Skrepnek GH, Sasane M, Snodgrass SM, Ballas SK.

J Med Econ. 2013;16(1):10-8. doi: 10.3111/13696998.2012.723081. Epub 2012 Sep 5.

PMID:
22947171
4.

Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.

Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Qiu Y, Duh MS, Paley C, Adams-Graves P.

J Med Econ. 2016;19(3):292-303. doi: 10.3111/13696998.2015.1117979. Epub 2015 Nov 30.

PMID:
26618853
5.

Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.

Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.

Am J Hematol. 2008 Apr;83(4):263-70.

6.

Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy.

Jordan L, Adams-Graves P, Kanter-Washko J, Oneal PA, Sasane M, Vekeman F, Bieri C, Magestro M, Marcellari A, Duh MS.

Curr Med Res Opin. 2015 Mar;31(3):513-23. doi: 10.1185/03007995.2014.998815. Epub 2014 Dec 31.

PMID:
25495135
7.

Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.

Blinder MA, Duh MS, Sasane M, Trahey A, Paley C, Vekeman F.

J Emerg Med. 2015 Oct;49(4):513-522.e1. doi: 10.1016/j.jemermed.2014.12.080. Epub 2015 Apr 21.

PMID:
25910824
8.

Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.

Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R.

Am J Hematol. 2011 Mar;86(3):273-7. doi: 10.1002/ajh.21968. Epub 2011 Feb 15.

9.

The cost of health care for children and adults with sickle cell disease.

Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG.

Am J Hematol. 2009 Jun;84(6):323-7. doi: 10.1002/ajh.21408.

10.

Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.

Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE; Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH).

Am J Hematol. 2013 Nov;88(11):932-8. doi: 10.1002/ajh.23547. Epub 2013 Aug 30.

11.

Clinical and economic burden of infused iron chelation therapy in the United States.

Payne KA, Desrosiers MP, Caro JJ, Baladi JF, Lordan N, Proskorovsky I, Ishak K, Rofail D.

Transfusion. 2007 Oct;47(10):1820-9.

PMID:
17880607
12.

Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases.

Koshy M, Weiner SJ, Miller ST, Sleeper LA, Vichinsky E, Brown AK, Khakoo Y, Kinney TR.

Blood. 1995 Nov 15;86(10):3676-84.

13.

Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.

Vekeman F, Cheng WY, Sasane M, Huynh L, Duh MS, Paley C, Mesa RA.

Leuk Lymphoma. 2015;56(10):2803-11. doi: 10.3109/10428194.2015.1016933. Epub 2015 Mar 30.

PMID:
25676036
14.

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.

Stallworth JR, Jerrell JM, Tripathi A.

Am J Hematol. 2010 Oct;85(10):795-7. doi: 10.1002/ajh.21772.

15.

Serum angiogenin level in sickle cell disease and beta thalassemia patients.

Matter RM, Abdelmaksoud AA, Shams MA, Bebawy EK.

Pediatr Hematol Oncol. 2014 Feb;31(1):50-6. doi: 10.3109/08880018.2013.876471.

PMID:
24483841
16.

Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.

Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C.

Eur J Haematol. 2010 Jan 1;84(1):72-8. doi: 10.1111/j.1600-0609.2009.01342.x.

PMID:
19732137
17.

Chelation treatment in sickle-cell-anaemia: much ado about nothing?

Lucania G, Vitrano A, Filosa A, Maggio A.

Br J Haematol. 2011 Sep;154(5):545-55. doi: 10.1111/j.1365-2141.2011.08769.x. Epub 2011 Jun 28. Review.

PMID:
21707578
18.

Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J.

JAMA. 2014 Sep 10;312(10):1033-48. doi: 10.1001/jama.2014.10517. Review. Erratum in: JAMA. 2014 Nov 12;312(18):1932. JAMA. 2015 Feb 17;313(7):729.

PMID:
25203083
19.
20.

Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.

Leitch HA, Chase JM, Goodman TA, Ezzat H, Rollins MD, Wong DH, Badawi M, Leger CS, Ramadan KM, Barnett MJ, Foltz LM, Vickars LM.

Hematol Oncol. 2010 Mar;28(1):40-8. doi: 10.1002/hon.902.

PMID:
19557769

Supplemental Content

Support Center